BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-12-07

AUTHORS

Michael S. Niederman, Jean Chastre, Kevin Corkery, James B. Fink, Charles-Edouard Luyt, Miguel Sánchez García

ABSTRACT

PurposeTo conduct a multicenter, randomized, placebo-controlled, double-blind, phase II study of BAY41-6551 (NCT01004445), an investigational drug–device combination of amikacin, formulated for inhalation, and a proprietary Pulmonary Drug Delivery System, for the treatment of Gram-negative pneumonia in mechanically ventilated patients.MethodsSixty-nine mechanically ventilated patients with Gram-negative pneumonia, a clinical pulmonary infection score ≥6, at risk for multidrug-resistant organisms, were randomized to BAY41-6551 400 mg every 12 h (q12h), 400 mg every 24 h (q24h) with aerosol placebo, or placebo q12h for 7–14 days, plus standard intravenous antibiotics. The combined primary endpoint was a tracheal aspirate amikacin maximum concentration ≥6,400 μg/mL (25 × 256 μg/mL reference minimum inhibitory concentration) and a ratio of area under the aspirate concentration–time curve (0–24 h) to minimum inhibitory concentration ≥100 on day 1.ResultsThe primary endpoint was achieved in 50% (6/12) and 16.7% (3/18) of patients in the q12h and q24h groups, respectively. Clinical cure rates, in the 48 patients getting ≥7 days of therapy, were 93.8% (15/16), 75.0% (12/16), and 87.5% (14/16) in the q12h, q24h, and placebo groups, respectively (p = 0.467). By the end of aerosol therapy, the mean number of antibiotics per patient per day was 0.9 in the q12h, 1.3 in the q24h, and 1.9 in the placebo groups, respectively (p = 0.02 for difference between groups). BAY41-6551 was well tolerated and attributed to two adverse events in one patient (mild bronchospasm).ConclusionsBAY41-6551 400 mg q12h warrants further clinical evaluation. More... »

PAGES

263-271

Journal

TITLE

Intensive Care Medicine

ISSUE

2

VOLUME

38

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00134-011-2420-0

DOI

http://dx.doi.org/10.1007/s00134-011-2420-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1023392555

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22147112


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aerosols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amikacin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Body Fluids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gram-Negative Bacterial Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Microbial Sensitivity Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pneumonia, Bacterial", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pneumonia, Ventilator-Associated", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Respiration, Artificial", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trachea", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Winthrop-University Hospital, 222 Station Plaza N., Suite 509, 11501, Mineola, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.281603.e", 
          "name": [
            "Department of Medicine, Winthrop-University Hospital, 222 Station Plaza N., Suite 509, 11501, Mineola, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Niederman", 
        "givenName": "Michael S.", 
        "id": "sg:person.01305416464.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305416464.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Piti\u00e9-Salp\u00e9tri\u00e8re, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.411439.a", 
          "name": [
            "H\u00f4pital Piti\u00e9-Salp\u00e9tri\u00e8re, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chastre", 
        "givenName": "Jean", 
        "id": "sg:person.0714077601.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714077601.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharmaceuticals Corporation (formerly Nektar Therapeutics), San Carlos, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation (formerly Nektar Therapeutics), San Carlos, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Corkery", 
        "givenName": "Kevin", 
        "id": "sg:person.0752144541.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752144541.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aerogen Limited (formerly Nektar Therapeutics), Galway, Ireland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Aerogen Limited (formerly Nektar Therapeutics), Galway, Ireland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fink", 
        "givenName": "James B.", 
        "id": "sg:person.0721371273.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721371273.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Piti\u00e9-Salp\u00e9tri\u00e8re, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.411439.a", 
          "name": [
            "H\u00f4pital Piti\u00e9-Salp\u00e9tri\u00e8re, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Luyt", 
        "givenName": "Charles-Edouard", 
        "id": "sg:person.01310337776.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310337776.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Cl\u00ednico San Carlos, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411068.a", 
          "name": [
            "Hospital Cl\u00ednico San Carlos, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garc\u00eda", 
        "givenName": "Miguel S\u00e1nchez", 
        "id": "sg:person.014757317051.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014757317051.56"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/cc8206", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010862289", 
          "https://doi.org/10.1186/cc8206"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00134-010-1879-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046735722", 
          "https://doi.org/10.1007/s00134-010-1879-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00134-009-1605-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033258941", 
          "https://doi.org/10.1007/s00134-009-1605-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-12-07", 
    "datePublishedReg": "2011-12-07", 
    "description": "PurposeTo conduct a multicenter, randomized, placebo-controlled, double-blind, phase II study of BAY41-6551 (NCT01004445), an investigational drug\u2013device combination of amikacin, formulated for inhalation, and a proprietary Pulmonary Drug Delivery System, for the treatment of Gram-negative pneumonia in mechanically ventilated patients.MethodsSixty-nine mechanically ventilated patients with Gram-negative pneumonia, a clinical pulmonary infection score \u22656, at risk for multidrug-resistant organisms, were randomized to BAY41-6551 400\u00a0mg every 12\u00a0h (q12h), 400\u00a0mg every 24\u00a0h (q24h) with aerosol placebo, or placebo q12h for 7\u201314\u00a0days, plus standard intravenous antibiotics. The combined primary endpoint was a tracheal aspirate amikacin maximum concentration \u22656,400\u00a0\u03bcg/mL (25\u00a0\u00d7\u00a0256\u00a0\u03bcg/mL reference minimum inhibitory concentration) and a ratio of area under the aspirate concentration\u2013time curve (0\u201324\u00a0h) to minimum inhibitory concentration \u2265100 on day 1.ResultsThe primary endpoint was achieved in 50% (6/12) and 16.7% (3/18) of patients in the q12h and q24h groups, respectively. Clinical cure rates, in the 48 patients getting \u22657\u00a0days of therapy, were 93.8% (15/16), 75.0% (12/16), and 87.5% (14/16) in the q12h, q24h, and placebo groups, respectively (p\u00a0=\u00a00.467). By the end of aerosol therapy, the mean number of antibiotics per patient per day was 0.9 in the q12h, 1.3 in the q24h, and 1.9 in the placebo groups, respectively (p\u00a0=\u00a00.02 for difference between groups). BAY41-6551 was well tolerated and attributed to two adverse events in one patient (mild bronchospasm).ConclusionsBAY41-6551 400\u00a0mg q12h warrants further clinical evaluation.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00134-011-2420-0", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1313639", 
        "issn": [
          "0342-4642", 
          "1432-1238"
        ], 
        "name": "Intensive Care Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "38"
      }
    ], 
    "keywords": [
      "Gram-negative pneumonia", 
      "placebo group", 
      "primary endpoint", 
      "Clinical Pulmonary Infection Score", 
      "standard intravenous antibiotics", 
      "phase II study", 
      "clinical cure rate", 
      "days of therapy", 
      "multidrug-resistant organisms", 
      "concentration-time curve", 
      "pulmonary drug delivery systems", 
      "drug-device combination", 
      "intravenous antibiotics", 
      "II study", 
      "adverse events", 
      "cure rate", 
      "minimum inhibitory concentration", 
      "clinical evaluation", 
      "amikacin concentrations", 
      "infection score", 
      "patients", 
      "q12h", 
      "BAY41", 
      "pneumonia", 
      "mean number", 
      "inhibitory concentration", 
      "q24h", 
      "placebo", 
      "ratio of area", 
      "therapy", 
      "endpoint", 
      "drug delivery systems", 
      "antibiotics", 
      "days", 
      "delivery system", 
      "group", 
      "multicenter", 
      "PurposeTo", 
      "amikacin", 
      "maximum concentration", 
      "inhalation", 
      "treatment", 
      "scores", 
      "risk", 
      "concentration", 
      "warrants", 
      "evaluation", 
      "study", 
      "rate", 
      "events", 
      "combination", 
      "number", 
      "ratio", 
      "end", 
      "curves", 
      "organisms", 
      "area", 
      "system", 
      "achieves"
    ], 
    "name": "BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia", 
    "pagination": "263-271", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1023392555"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00134-011-2420-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22147112"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00134-011-2420-0", 
      "https://app.dimensions.ai/details/publication/pub.1023392555"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_553.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00134-011-2420-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00134-011-2420-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00134-011-2420-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00134-011-2420-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00134-011-2420-0'


 

This table displays all metadata directly associated to this object as RDF triples.

239 TRIPLES      21 PREDICATES      102 URIs      91 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00134-011-2420-0 schema:about N01afe0ba5334496a8eec72c026954045
2 N057737d080634a5e8ae77265ad94e0b8
3 N409bcbc9ad22409cab5217ffeede05c7
4 N45b83a098d634fc98a083391bdb69d71
5 N4f6f750eafc1401d886dde1df47ec4c1
6 N55cf28f657ff45b29ecface55b389955
7 N7d40d64a17944f2d8c2c066c4815c3e5
8 N8154bf43628041ccb86cac65a0920ecb
9 N8e518ed8a2894476bbd8156dbd6a9823
10 Nc68149d2f539494898dd9df851b05748
11 Nc7212dbe02da4545abe0581cc24d26e8
12 Nc9d3d579ebca470c8406a0be952e981d
13 Nd0564af5e1ac41129ac386ba73a8921d
14 Nef77c7c8268d4965bc6c60a4131ed8f2
15 Nf68811b5893641f59cd64c51362d1dce
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author N2639fa0c7e394800992e926a1cf9d9f0
19 schema:citation sg:pub.10.1007/s00134-009-1605-2
20 sg:pub.10.1007/s00134-010-1879-4
21 sg:pub.10.1186/cc8206
22 schema:datePublished 2011-12-07
23 schema:datePublishedReg 2011-12-07
24 schema:description PurposeTo conduct a multicenter, randomized, placebo-controlled, double-blind, phase II study of BAY41-6551 (NCT01004445), an investigational drug–device combination of amikacin, formulated for inhalation, and a proprietary Pulmonary Drug Delivery System, for the treatment of Gram-negative pneumonia in mechanically ventilated patients.MethodsSixty-nine mechanically ventilated patients with Gram-negative pneumonia, a clinical pulmonary infection score ≥6, at risk for multidrug-resistant organisms, were randomized to BAY41-6551 400 mg every 12 h (q12h), 400 mg every 24 h (q24h) with aerosol placebo, or placebo q12h for 7–14 days, plus standard intravenous antibiotics. The combined primary endpoint was a tracheal aspirate amikacin maximum concentration ≥6,400 μg/mL (25 × 256 μg/mL reference minimum inhibitory concentration) and a ratio of area under the aspirate concentration–time curve (0–24 h) to minimum inhibitory concentration ≥100 on day 1.ResultsThe primary endpoint was achieved in 50% (6/12) and 16.7% (3/18) of patients in the q12h and q24h groups, respectively. Clinical cure rates, in the 48 patients getting ≥7 days of therapy, were 93.8% (15/16), 75.0% (12/16), and 87.5% (14/16) in the q12h, q24h, and placebo groups, respectively (p = 0.467). By the end of aerosol therapy, the mean number of antibiotics per patient per day was 0.9 in the q12h, 1.3 in the q24h, and 1.9 in the placebo groups, respectively (p = 0.02 for difference between groups). BAY41-6551 was well tolerated and attributed to two adverse events in one patient (mild bronchospasm).ConclusionsBAY41-6551 400 mg q12h warrants further clinical evaluation.
25 schema:genre article
26 schema:isAccessibleForFree false
27 schema:isPartOf N1b6e152e186747039f67c21a1b151314
28 N872bceef965248b7aafce5ee10a4e04f
29 sg:journal.1313639
30 schema:keywords BAY41
31 Clinical Pulmonary Infection Score
32 Gram-negative pneumonia
33 II study
34 PurposeTo
35 achieves
36 adverse events
37 amikacin
38 amikacin concentrations
39 antibiotics
40 area
41 clinical cure rate
42 clinical evaluation
43 combination
44 concentration
45 concentration-time curve
46 cure rate
47 curves
48 days
49 days of therapy
50 delivery system
51 drug delivery systems
52 drug-device combination
53 end
54 endpoint
55 evaluation
56 events
57 group
58 infection score
59 inhalation
60 inhibitory concentration
61 intravenous antibiotics
62 maximum concentration
63 mean number
64 minimum inhibitory concentration
65 multicenter
66 multidrug-resistant organisms
67 number
68 organisms
69 patients
70 phase II study
71 placebo
72 placebo group
73 pneumonia
74 primary endpoint
75 pulmonary drug delivery systems
76 q12h
77 q24h
78 rate
79 ratio
80 ratio of area
81 risk
82 scores
83 standard intravenous antibiotics
84 study
85 system
86 therapy
87 treatment
88 warrants
89 schema:name BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia
90 schema:pagination 263-271
91 schema:productId N102fa549c424429e94017d3b26824ec1
92 N49e51b147c0b46bb89003baecdf94b31
93 Nb7469cd304e74cf3952d37aeb8d0761b
94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023392555
95 https://doi.org/10.1007/s00134-011-2420-0
96 schema:sdDatePublished 2022-09-02T15:55
97 schema:sdLicense https://scigraph.springernature.com/explorer/license/
98 schema:sdPublisher N8ea9d694e85b47a78fd87550d687d924
99 schema:url https://doi.org/10.1007/s00134-011-2420-0
100 sgo:license sg:explorer/license/
101 sgo:sdDataset articles
102 rdf:type schema:ScholarlyArticle
103 N01afe0ba5334496a8eec72c026954045 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Humans
105 rdf:type schema:DefinedTerm
106 N057737d080634a5e8ae77265ad94e0b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Aerosols
108 rdf:type schema:DefinedTerm
109 N102fa549c424429e94017d3b26824ec1 schema:name dimensions_id
110 schema:value pub.1023392555
111 rdf:type schema:PropertyValue
112 N1b6e152e186747039f67c21a1b151314 schema:volumeNumber 38
113 rdf:type schema:PublicationVolume
114 N1cce901b82974b3e862c776249205c2e rdf:first sg:person.01310337776.72
115 rdf:rest Nad483271a7b94e1fb7d0216f2a75a148
116 N2639fa0c7e394800992e926a1cf9d9f0 rdf:first sg:person.01305416464.55
117 rdf:rest N2dddd36844d842afa8de0d00ec029310
118 N2dddd36844d842afa8de0d00ec029310 rdf:first sg:person.0714077601.27
119 rdf:rest N608e7a203a4040c39020d5cb0ae28fc5
120 N409bcbc9ad22409cab5217ffeede05c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Amikacin
122 rdf:type schema:DefinedTerm
123 N45b83a098d634fc98a083391bdb69d71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Male
125 rdf:type schema:DefinedTerm
126 N49e51b147c0b46bb89003baecdf94b31 schema:name pubmed_id
127 schema:value 22147112
128 rdf:type schema:PropertyValue
129 N4f6f750eafc1401d886dde1df47ec4c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Anti-Bacterial Agents
131 rdf:type schema:DefinedTerm
132 N55cf28f657ff45b29ecface55b389955 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Body Fluids
134 rdf:type schema:DefinedTerm
135 N5cf1d9acb38c4ffcbd8e39bd54fb1985 rdf:first sg:person.0721371273.52
136 rdf:rest N1cce901b82974b3e862c776249205c2e
137 N608e7a203a4040c39020d5cb0ae28fc5 rdf:first sg:person.0752144541.89
138 rdf:rest N5cf1d9acb38c4ffcbd8e39bd54fb1985
139 N7d40d64a17944f2d8c2c066c4815c3e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Pneumonia, Bacterial
141 rdf:type schema:DefinedTerm
142 N8154bf43628041ccb86cac65a0920ecb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Trachea
144 rdf:type schema:DefinedTerm
145 N872bceef965248b7aafce5ee10a4e04f schema:issueNumber 2
146 rdf:type schema:PublicationIssue
147 N8e518ed8a2894476bbd8156dbd6a9823 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Female
149 rdf:type schema:DefinedTerm
150 N8ea9d694e85b47a78fd87550d687d924 schema:name Springer Nature - SN SciGraph project
151 rdf:type schema:Organization
152 Nad483271a7b94e1fb7d0216f2a75a148 rdf:first sg:person.014757317051.56
153 rdf:rest rdf:nil
154 Nb7469cd304e74cf3952d37aeb8d0761b schema:name doi
155 schema:value 10.1007/s00134-011-2420-0
156 rdf:type schema:PropertyValue
157 Nc68149d2f539494898dd9df851b05748 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Microbial Sensitivity Tests
159 rdf:type schema:DefinedTerm
160 Nc7212dbe02da4545abe0581cc24d26e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Gram-Negative Bacterial Infections
162 rdf:type schema:DefinedTerm
163 Nc9d3d579ebca470c8406a0be952e981d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Respiration, Artificial
165 rdf:type schema:DefinedTerm
166 Nd0564af5e1ac41129ac386ba73a8921d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Pneumonia, Ventilator-Associated
168 rdf:type schema:DefinedTerm
169 Nef77c7c8268d4965bc6c60a4131ed8f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Double-Blind Method
171 rdf:type schema:DefinedTerm
172 Nf68811b5893641f59cd64c51362d1dce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Middle Aged
174 rdf:type schema:DefinedTerm
175 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
176 schema:name Medical and Health Sciences
177 rdf:type schema:DefinedTerm
178 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
179 schema:name Clinical Sciences
180 rdf:type schema:DefinedTerm
181 sg:journal.1313639 schema:issn 0342-4642
182 1432-1238
183 schema:name Intensive Care Medicine
184 schema:publisher Springer Nature
185 rdf:type schema:Periodical
186 sg:person.01305416464.55 schema:affiliation grid-institutes:grid.281603.e
187 schema:familyName Niederman
188 schema:givenName Michael S.
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305416464.55
190 rdf:type schema:Person
191 sg:person.01310337776.72 schema:affiliation grid-institutes:grid.411439.a
192 schema:familyName Luyt
193 schema:givenName Charles-Edouard
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310337776.72
195 rdf:type schema:Person
196 sg:person.014757317051.56 schema:affiliation grid-institutes:grid.411068.a
197 schema:familyName García
198 schema:givenName Miguel Sánchez
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014757317051.56
200 rdf:type schema:Person
201 sg:person.0714077601.27 schema:affiliation grid-institutes:grid.411439.a
202 schema:familyName Chastre
203 schema:givenName Jean
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714077601.27
205 rdf:type schema:Person
206 sg:person.0721371273.52 schema:affiliation grid-institutes:None
207 schema:familyName Fink
208 schema:givenName James B.
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721371273.52
210 rdf:type schema:Person
211 sg:person.0752144541.89 schema:affiliation grid-institutes:grid.418424.f
212 schema:familyName Corkery
213 schema:givenName Kevin
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752144541.89
215 rdf:type schema:Person
216 sg:pub.10.1007/s00134-009-1605-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033258941
217 https://doi.org/10.1007/s00134-009-1605-2
218 rdf:type schema:CreativeWork
219 sg:pub.10.1007/s00134-010-1879-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046735722
220 https://doi.org/10.1007/s00134-010-1879-4
221 rdf:type schema:CreativeWork
222 sg:pub.10.1186/cc8206 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010862289
223 https://doi.org/10.1186/cc8206
224 rdf:type schema:CreativeWork
225 grid-institutes:None schema:alternateName Aerogen Limited (formerly Nektar Therapeutics), Galway, Ireland
226 schema:name Aerogen Limited (formerly Nektar Therapeutics), Galway, Ireland
227 rdf:type schema:Organization
228 grid-institutes:grid.281603.e schema:alternateName Department of Medicine, Winthrop-University Hospital, 222 Station Plaza N., Suite 509, 11501, Mineola, NY, USA
229 schema:name Department of Medicine, Winthrop-University Hospital, 222 Station Plaza N., Suite 509, 11501, Mineola, NY, USA
230 rdf:type schema:Organization
231 grid-institutes:grid.411068.a schema:alternateName Hospital Clínico San Carlos, Madrid, Spain
232 schema:name Hospital Clínico San Carlos, Madrid, Spain
233 rdf:type schema:Organization
234 grid-institutes:grid.411439.a schema:alternateName Hôpital Pitié-Salpétrière, Paris, France
235 schema:name Hôpital Pitié-Salpétrière, Paris, France
236 rdf:type schema:Organization
237 grid-institutes:grid.418424.f schema:alternateName Novartis Pharmaceuticals Corporation (formerly Nektar Therapeutics), San Carlos, CA, USA
238 schema:name Novartis Pharmaceuticals Corporation (formerly Nektar Therapeutics), San Carlos, CA, USA
239 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...